Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To evaluate the ocular hypotensive efficacy of fixed-dose combinations of the Rho kinase inhibitor and norepinephrine transport inhibitor AR-13324 (0.01% and 0.02%) and latanoprost (PG324 Ophthalmic Solution) relative to the active components AR-13324 0.02% and latanoprost 0.005%, used bilaterally at night.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Br J Ophthalmol

Title: The British journal of ophthalmology

Publisher: BMJ

ISSN (Electronic): 1468-2079

ISSN (Print): 0007-1161

Publication date (Electronic): Mar 2016

Volume: 100

Issue: 3

Affiliations

[1 ] Sacramento Eye Consultants, Sacramento, California, USA.

[2 ] Aerie Pharmaceuticals Inc., Bridgewater, Bridgewater, New Jersey, USA/Research Triangle Park, North Carolina, USA SDC Inc., Tempe, Arizona, USA.

[3 ] SDC Inc., Tempe, Arizona, USA.

[4 ] PharmaLogic Development Inc., San Rafael, California, USA.

Article

Publisher Item ID: bjophthalmol-2015-306778

DOI: 10.1136/bjophthalmol-2015-306778

PubMed ID: 26209587

SO-VID: 34e35330-81c4-4212-bfb2-f25168b95c5c

History

Keywords: Glaucoma,Intraocular pressure

Data availability:

Keywords: Glaucoma, Intraocular pressure

Comments

Comment on this article

scite_

Cited by 25

See all cited by